CY1105957T1 - Χρηση οιστρογονων ενωσεων σε συνδυασμο με ενωσεις προγεστογονου (progestogen) σε θepαπεια ορμονικης αντικαταστασης - Google Patents
Χρηση οιστρογονων ενωσεων σε συνδυασμο με ενωσεις προγεστογονου (progestogen) σε θepαπεια ορμονικης αντικαταστασηςInfo
- Publication number
- CY1105957T1 CY1105957T1 CY20071100107T CY071100107T CY1105957T1 CY 1105957 T1 CY1105957 T1 CY 1105957T1 CY 20071100107 T CY20071100107 T CY 20071100107T CY 071100107 T CY071100107 T CY 071100107T CY 1105957 T1 CY1105957 T1 CY 1105957T1
- Authority
- CY
- Cyprus
- Prior art keywords
- compound
- compounds
- progestogen
- estrogen
- hormone replacement
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 8
- 229940011871 estrogen Drugs 0.000 title abstract 3
- 239000000262 estrogen Substances 0.000 title abstract 3
- 239000000583 progesterone congener Substances 0.000 title abstract 3
- 238000002657 hormone replacement therapy Methods 0.000 title 1
- 239000000126 substance Substances 0.000 abstract 4
- 241000124008 Mammalia Species 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 239000002243 precursor Substances 0.000 abstract 2
- 239000003098 androgen Substances 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 230000001076 estrogenic effect Effects 0.000 abstract 1
- 239000005556 hormone Substances 0.000 abstract 1
- 229940088597 hormone Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Μια διάσταση της παρούσας εφεύρεσης σχετίζεται με την μέθοδο ορμονικής αντικατάστασης στα θηλαστικά, η οποία μέθοδος περιλαμβάνει την χορήγηση δια της στοματικής οδού μιας ένωσης οιστρογόνου και μιας ένωσης προγεστογόνου σε ένα θηλαστικό σε ένα ποσό αποτελεσματικό προκειμένου να προληφθούν ή να θεραπευτούν τα συμπτώματα υποοιστρογονισμού, όπου η ένωση οιστρογόνου έχει επιλεγεί από μια ομάδα η οποία αποτελείται από : ουσίες οι οποίες απεικονίζονται από τον χημικό τύπο ( I ) στον οποίο τύπο τα R1, R2, R3, R4 ανεξάρτητα είναι ένα άτομο υδρογόνου, μια ομάδα υδροξυλίου ή μια ομάδα αλκοξύ με 1 - 5 άτομα άνθρακα ˙ κάθε ένα από τα R5, R6, R7 είναι μια ομάδα υδροξυλίου ˙ και όχι περισσότερα από 3 εκ των R1, R2, R3, R4 είναι άτομα υδρογόνου ˙ προδρόμους ικανούς να ελευθερώσουν μια ουσία σύμφωνα με τον προαναφερθέν χημικό τύπο όταν χρησιμοποιούνται στην παρούσα μέθοδο ˙ και μείγματα ενός ή περισσοτέρων εκ των προαναφερθέντων ουσιών και / ή προδρόμων. Μια άλλη διάσταση της εφεύρεσης αφορά σε ένα φαρμακευτικό κιτίο το οποίο περιλαμβάνει μονάδες δοσολογίας δια της στοματικής οδού οι οποίες περιλαμβάνουν την προαναφερθείσα ένωση οιστρογόνου και μια ένωση προγεστογόνου, καθώς και μια ένωση ανδρογόνου.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01204377 | 2001-11-15 | ||
EP02075695 | 2002-02-21 | ||
PCT/NL2002/000332 WO2003041718A1 (en) | 2001-11-15 | 2002-05-23 | Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy |
EP02738962A EP1446128B1 (en) | 2001-11-15 | 2002-05-23 | Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1105957T1 true CY1105957T1 (el) | 2011-04-06 |
Family
ID=26077031
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20071100107T CY1105957T1 (el) | 2001-11-15 | 2007-01-29 | Χρηση οιστρογονων ενωσεων σε συνδυασμο με ενωσεις προγεστογονου (progestogen) σε θepαπεια ορμονικης αντικαταστασης |
Country Status (10)
Country | Link |
---|---|
US (1) | US8026228B2 (el) |
EP (1) | EP1446128B1 (el) |
AT (1) | ATE347365T1 (el) |
CA (1) | CA2467222C (el) |
CY (1) | CY1105957T1 (el) |
DE (1) | DE60216630T2 (el) |
DK (1) | DK1446128T3 (el) |
ES (1) | ES2278925T3 (el) |
PT (1) | PT1446128E (el) |
WO (1) | WO2003041718A1 (el) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040214807A1 (en) * | 1993-08-06 | 2004-10-28 | D'amato Robert J. | Estrogenic compounds as anti-mitotic agents |
US6346510B1 (en) * | 1995-10-23 | 2002-02-12 | The Children's Medical Center Corporation | Therapeutic antiangiogenic endostatin compositions |
ES2296943T3 (es) * | 2001-05-23 | 2008-05-01 | Pantarhei Bioscience B.V. | Sistema de administracion de un medicamento estrogeno tetrahidroxilado destinado a la contracepcion hormonal. |
SI1562976T1 (sl) | 2002-11-08 | 2010-08-31 | Pantarhei Bioscience Bv | Sinteza estetrola preko steroidov, izvedenih iz estrona |
US7371741B2 (en) * | 2003-05-28 | 2008-05-13 | Entremed, Inc. | Estradiol derivatives and pharmaceutical compositions using same |
US20050032758A1 (en) * | 2003-06-25 | 2005-02-10 | Ina Rudolph | Hormone replacement therapy and depression |
CA2558014A1 (en) | 2004-03-12 | 2005-09-29 | Entremed, Inc. | Antiangiogenic agents |
US20070004689A1 (en) * | 2004-03-12 | 2007-01-04 | Agoston Gregory E | Antiangiogenic agents |
JP2008521822A (ja) * | 2004-11-29 | 2008-06-26 | エントレメッド インコーポレイテッド | 抗血管形成剤を投与する方法、およびそれを用いて疾病を治療する方法 |
WO2007059111A2 (en) * | 2005-11-14 | 2007-05-24 | Entremed, Inc. | Anti-angiogenic activity of 2-methoxyestradiol in combination with anti-cancer agents |
US20070176403A1 (en) * | 2006-02-01 | 2007-08-02 | Dennis Calderone | Air adjustable seat |
US8399440B2 (en) * | 2006-03-20 | 2013-03-19 | Entremed, Inc. | Disease modifying anti-arthritic activity of 2-methoxyestradiol |
US20100087407A1 (en) * | 2006-08-04 | 2010-04-08 | James Symons | use of aromatase inhibitors |
EP2114412B1 (en) * | 2007-01-08 | 2010-07-14 | Pantarhei Bioscience B.V. | Method of treating or preventing infertility in a female mammal and pharmaceutical kit for use in such method |
US20080234243A1 (en) * | 2007-01-31 | 2008-09-25 | Lavallee Theresa M | Method of treating amyloidosis mediated diseases |
WO2009075838A2 (en) * | 2007-12-10 | 2009-06-18 | Meditrina Pharmaceuticals, Inc. | Treatment of menorrhagia with aromatase inhibitor |
US9446051B2 (en) * | 2009-10-19 | 2016-09-20 | The Population Council, Inc. | Neuroprotection and myelin repair using nestorone® |
AU2010308308B2 (en) | 2009-10-19 | 2013-11-28 | The Population Council, Inc. | Neuroprotection and myelin repair using nestorone® |
US11053274B2 (en) | 2011-06-01 | 2021-07-06 | Estetra S.P.R.L. | Process for the production of estetrol intermediates |
CA2835979C (en) | 2011-06-01 | 2018-05-01 | Estetra S.A. | Process for the production of estetrol intermediates |
EP2383279A1 (en) | 2011-07-19 | 2011-11-02 | Pantarhei Bioscience B.V. | Process for the preparation of estetrol |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
JP6285866B2 (ja) | 2011-11-23 | 2018-02-28 | セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. | 天然複合ホルモン補充製剤および療法 |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
WO2013034780A2 (en) | 2012-12-20 | 2013-03-14 | Crystal Pharma, S.A.U. | Process for the preparation of estetrol and related compounds |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
CA2924255C (en) | 2013-09-18 | 2022-11-22 | Crystal Pharma, S.A.U. | Process for the preparation of estetrol |
EA032306B1 (ru) | 2013-12-12 | 2019-05-31 | Донеста Байосайенс Б.В. | Орально распадающаяся твердая фармацевтическая единица дозирования, содержащая эстетрольный компонент, ее применение и способ получения |
KR20170005819A (ko) | 2014-05-22 | 2017-01-16 | 쎄러퓨틱스엠디, 인코퍼레이티드 | 천연 복합 호르몬 대체 제형 및 요법 |
GEP20217308B (en) * | 2015-06-18 | 2021-10-25 | Estetra Sprl | Orodispersible dosage unit containing an estetrol component |
PL3310333T3 (pl) | 2015-06-18 | 2020-07-13 | Estetra Sprl | Ulegająca rozpadowi w jamie ustnej jednostka dawkowana zawierająca składnik estetrolowy |
DK3310346T3 (da) | 2015-06-18 | 2021-05-25 | Estetra Sprl | Orodispersibel tablet indeholdende estetrol |
MA44205B1 (fr) | 2015-06-18 | 2021-04-30 | Estetra Sprl | Comprimé orodispersible comprenant estetrol |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
WO2017173071A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
CA3178291A1 (en) | 2016-08-05 | 2018-04-12 | Estetra Srl | Method for the management of dysmenorrhea and menstrual pain |
US10285998B1 (en) | 2018-04-04 | 2019-05-14 | The Menopause Method, Inc. | Composition and method to aid in hormone replacement therapy |
JOP20200260A1 (ar) * | 2018-04-19 | 2019-10-19 | Estetra Sprl | مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث |
TWI801561B (zh) | 2018-04-19 | 2023-05-11 | 比利時商依思特拉私人有限責任公司 | 化合物及其用於緩解絕經相關症狀的用途 |
HU231240B1 (hu) | 2019-09-03 | 2022-04-28 | Richter Gedeon Nyrt. | Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására |
CA3237490A1 (en) * | 2021-11-29 | 2023-06-01 | Estetra Srl | Compositions for preventing or treating skin aging |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3440320A (en) | 1964-06-18 | 1969-04-22 | Mortimer D Sackler | Chelated suppository and method of using same |
US3797494A (en) | 1969-04-01 | 1974-03-19 | Alza Corp | Bandage for the administration of drug by controlled metering through microporous materials |
DE2336434A1 (de) | 1973-07-13 | 1975-04-17 | Schering Ag | 1.3-oxygenierte 8 alpha-oestratriene |
DE2336433A1 (de) | 1973-07-13 | 1975-04-03 | Schering Ag | 1.3-oxygenierte 8 alpha-oestratriene |
DE2426779A1 (de) | 1974-05-31 | 1975-12-18 | Schering Ag | 1.3-oxygenierte 8 alpha-oestratriene |
US4722941A (en) | 1978-06-07 | 1988-02-02 | Kali-Chemie Pharma Gmbh | Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof |
US4460372A (en) | 1981-02-17 | 1984-07-17 | Alza Corporation | Percutaneous absorption enhancer dispenser for use in coadministering drug and percutaneous absorption enhancer |
US4573996A (en) | 1984-01-03 | 1986-03-04 | Jonergin, Inc. | Device for the administration of an active agent to the skin or mucosa |
US4624665A (en) | 1984-10-01 | 1986-11-25 | Biotek, Inc. | Method of transdermal drug delivery |
US4937238A (en) | 1986-03-04 | 1990-06-26 | The Board Of Regents Of The University Of Nebraska | Prevention of mammary carcinoma |
US4762717A (en) | 1986-03-21 | 1988-08-09 | The General Hospital Corporation | Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use as a contraceptive |
US5223261A (en) | 1988-02-26 | 1993-06-29 | Riker Laboratories, Inc. | Transdermal estradiol delivery system |
US5043331A (en) | 1989-06-15 | 1991-08-27 | Orion-Yhtyma Oy | Treatment of postmenopausal disorders |
US5130137A (en) | 1989-08-09 | 1992-07-14 | The General Hospital Corporation | Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use in treating benign ovarian secretory disorders |
JPH04235171A (ja) | 1990-07-26 | 1992-08-24 | Sumitomo Chem Co Ltd | スルホヒドロキサム酸誘導体、その製造法およびそれを有効成分とする除草剤 |
US5063507A (en) | 1990-09-14 | 1991-11-05 | Plains Cotton Cooperative Association | Goods database employing electronic title or documentary-type title |
US5340586A (en) | 1991-04-12 | 1994-08-23 | University Of Southern California | Methods and formulations for use in treating oophorectomized women |
US5211952A (en) | 1991-04-12 | 1993-05-18 | University Of Southern California | Contraceptive methods and formulations for use therein |
US5340585A (en) | 1991-04-12 | 1994-08-23 | University Of Southern California | Method and formulations for use in treating benign gynecological disorders |
US5468736A (en) | 1993-02-25 | 1995-11-21 | The Medical College Of Hampton Road | Hormone replacement therapy |
NL9301562A (nl) | 1993-09-09 | 1995-04-03 | Saturnus Ag | Preparaat voor substitutietherapie. |
DE4344405C2 (de) * | 1993-12-24 | 1995-12-07 | Marika Dr Med Ehrlich | Ovulationshemmendes Mittel und Verfahren zur hormonalen Kontrazeption |
WO1996003929A1 (en) | 1994-08-04 | 1996-02-15 | Biex, Inc. | Method for prediction of premature delivery using estetrol (e4) as an indicator |
DE4429374C1 (de) | 1994-08-12 | 1996-02-01 | Jenapharm Gmbh | Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente |
WO1998058657A1 (en) | 1997-06-20 | 1998-12-30 | Akzo Nobel N.V. | Gonadotropin releasing hormone antagonist |
DE19739916C2 (de) | 1997-09-11 | 2001-09-13 | Hesch Rolf Dieter | Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen |
US20020013304A1 (en) * | 1997-10-28 | 2002-01-31 | Wilson Leland F. | As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness |
US6214815B1 (en) * | 1998-12-23 | 2001-04-10 | Ortho-Mcneil Pharmaceuticals, Inc. | Triphasic oral contraceptive |
DE19917930A1 (de) | 1999-04-15 | 2000-10-19 | Schering Ag | Ent-Steroide als selektiv wirksame Estrogene |
AU4543200A (en) | 1999-04-16 | 2000-11-02 | Dittgen, Michael | Pharmaceutical or cosmetic compositions for the local, intradermal application of hormones |
US7273932B1 (en) | 1999-05-28 | 2007-09-25 | The University Of Cincinnati | Antisense oligonucleotides for fertility and menstrual cycle regulation and for chemopreventive and chemotherapeutic use |
WO2001030356A1 (fr) | 1999-10-25 | 2001-05-03 | Laboratoire Theramex | Composition hormonale a base d'un progestatif et d'un estrogene et son utilisation |
AU2001259847B9 (en) | 2000-05-12 | 2006-08-10 | Oregon Health And Science University | Method of treating immune pathologies with low dose estrogen |
US6936599B2 (en) | 2001-04-25 | 2005-08-30 | The Regents Of The University Of California | Estriol therapy for multiple sclerosis and other autoimmune diseases |
EP1260225A1 (en) | 2001-05-18 | 2002-11-27 | Pantarhei Bioscience B.V. | A pharmaceutical composition for use in hormone replacement therapy |
-
2002
- 2002-05-23 US US10/495,707 patent/US8026228B2/en active Active
- 2002-05-23 PT PT02738962T patent/PT1446128E/pt unknown
- 2002-05-23 ES ES02738962T patent/ES2278925T3/es not_active Expired - Lifetime
- 2002-05-23 AT AT02738962T patent/ATE347365T1/de not_active IP Right Cessation
- 2002-05-23 WO PCT/NL2002/000332 patent/WO2003041718A1/en active IP Right Grant
- 2002-05-23 DK DK02738962T patent/DK1446128T3/da active
- 2002-05-23 EP EP02738962A patent/EP1446128B1/en not_active Expired - Lifetime
- 2002-05-23 CA CA2467222A patent/CA2467222C/en not_active Expired - Lifetime
- 2002-05-23 DE DE60216630T patent/DE60216630T2/de not_active Expired - Lifetime
-
2007
- 2007-01-29 CY CY20071100107T patent/CY1105957T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
DE60216630D1 (de) | 2007-01-18 |
DE60216630T2 (de) | 2007-09-20 |
EP1446128B1 (en) | 2006-12-06 |
WO2003041718A1 (en) | 2003-05-22 |
DK1446128T3 (da) | 2007-04-02 |
ATE347365T1 (de) | 2006-12-15 |
CA2467222A1 (en) | 2003-05-22 |
PT1446128E (pt) | 2007-03-30 |
ES2278925T3 (es) | 2007-08-16 |
US20050070488A1 (en) | 2005-03-31 |
CA2467222C (en) | 2010-06-08 |
US8026228B2 (en) | 2011-09-27 |
EP1446128A1 (en) | 2004-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1105957T1 (el) | Χρηση οιστρογονων ενωσεων σε συνδυασμο με ενωσεις προγεστογονου (progestogen) σε θepαπεια ορμονικης αντικαταστασης | |
CY1108093T1 (el) | Συστημα παραδοσης φαρμακων που αποτελειται απο τετραϋδροξυλιοποιημενο οιστρογονο για χρηση στην ορμονικη αντισυλληψη | |
CY1105766T1 (el) | Χρηση συνθεσεων που εμπepιεχουν ενα οιστρογονικο συστατικο για τη θepαπευτικη αγωγη και προληψη των μυοσκελετικων πονων | |
PE55998A1 (es) | Derivados 19-nor-pregneno substituidos | |
CY1105883T1 (el) | Μεθοδος θepαπειας ή προληψης διαταραχων οπου μεσολαβει το ανοσοποιητικο και φαρμακευτικο παρασκευασμα για χρηση σε αυτη | |
CY1106674T1 (el) | Αζαδικυκλικοι ετεροκυκλοι σαν ρυθμιστες υποδοχεα κανναβινοειδους | |
HUP0100568A2 (hu) | 11béta-Halogén-7alfa-helyettesített-ösztratriének, alkalmazásuk gyógyászati készítmények előállítására, valamint ilyen vegyületeket tartalmazó gyógyászati készítmények | |
AR023727A1 (es) | Compuestos empleados en el tratamiento de padecimientos inflamatorios | |
MXPA03001072A (es) | El uso de bencilidenaminoguanidinas e hidroxiguanidinas como ligandos de receptor de melanocortina. | |
ECSP066405A (es) | Compuestos de aril o heteroaril amida | |
CY1109498T1 (el) | 18-μεθυλο-19-νορ-17-πρεγν-4-ενο-21,17-καρβολακτονες καθως και φαρμακευτικα σκευασματα που τις περιεχουν | |
NO950275L (no) | Kombinasjonsbehandling for osteoporose | |
SV1998000008A (es) | Inhibisores de sulfamida-metaloproteasa. ref. ran 4070\114 | |
KR950032267A (ko) | 11,21-비스페닐-19-노르프레그난 유도체 | |
ATE241623T1 (de) | Azindolethylaminderivate als nikotin-acetylcholin-rezeptor bindung verbindungen | |
HUP9903707A2 (hu) | 17Béta-karboxi-,-tio-karboxi-vagy -amido-androsztánszármazékok laktonszármazékai, előállításuk, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények | |
BRPI0406780A (pt) | Novos compostos | |
AR007108A1 (es) | Agentes antitumorales y antivirales alquilantes, procedimiento para su preparacion, utilizacion de los mismos para la fabricacion de un medicamento y composicion farmaceutica que contiene a dichos agentes. | |
DE69933885D1 (de) | Triphenylbutenderivate zur behandlung von neurologischen störungen | |
ATE154607T1 (de) | Neue steroide | |
BR9708418A (pt) | Amino-e trifenil-s-triazinas hodroxissubstituídas como estabilizadores | |
DE60000978T2 (de) | 22r-hydroxycholesta-8,14-diene derivate zur hemmung der meiose | |
HUP0302820A2 (hu) | CNS rendellenességek kezelésében hasznos indolszármazékok és ezeket tartalmazó gyógyszerkészítmények | |
HUP0301592A2 (hu) | 16alfa-metil- vagy etil-szubsztituált ösztrogének és ezeket tartalmazó gyógyszerkészítmények | |
ATE279182T1 (de) | Verwendung spezieller verbindungen zur prophylaxe und therapie von hepatitis c |